BioSpace News Archive

Strategikon Pharma announced today the release of Clinical Maestro® SOURCE version 3.0.

Cleveland Diagnostics, Inc. announced that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection.

Horizon Therapeutics plc announced that Dara Mann, vice president, marketing, ophthalmology, has been named a 2022 Healthcare Businesswomen’s Association Rising Star.

Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today presented updates to its two lead programs at TIDES USA 2022: Oligonucleotide & Peptide Therapeutics Conference.

Eli Lilly and Company and Incyte announced the U.S. Food and Drug Administration has approved OLUMIANT® for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first.

Immunocore Reports today announced its financial results for the first quarter ended March 31, 2022 and provided a business update.

uniQure N.V. announced that the Company granted equity awards to 32 newly hired employees as a material inducement to commencing their employment.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that clinical data from the Phase 1/2 ABILITY (A Beta-only IL-2 ImmunoTherapY) study of MDNA11.

CareDx, Inc. today announced it will be presenting the latest information on its AlloSeq® portfolio of pre- and post-transplant solutions for human leukocyte antigen (HLA) at this year’s EFI 2022 Conference.

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), is pleased to announce the grant of patent application no. 15/753,882 entitled “USE OF VDAS TO ENHANCE IMMUNOMODULATING THERAPIES AGAINST TUMORS” by the US Patent Office.